Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTAP101 in Pediatric Participants With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
NCT07494045Phase 2Recruiting
- Sponsor
- OPKO Health
- Start
- Aug 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of CTAP101 in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD), Vitamin D deficiency (VDD), sponsored by OPKO Health. Started Aug 2026; status: recruiting.
02
Drugs
CTAP101
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on NCT07494045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07494045.